New findings on hormonal contraceptive patch shared at ACOG meeting
- New hormonal contraceptive patch data presented
- Focus on low-dose estrogen
- Showcased at ACOG annual meeting
Viatris has announced several data presentations regarding their investigational low-dose estrogen combined hormonal contraceptive patch. This new weekly patch aims to provide an alternative method for contraception for women seeking effective birth control options. The findings were shared during the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting.
The data presented highlighted various aspects of the hormonal contraceptive patch, including its effectiveness and safety profile. Viatris aimed to emphasize how this low-dose estrogen option could meet the needs of women looking for flexible contraceptive methods. The research findings are particularly relevant to discussions about advancements in women's health and contraceptive technology.
At the ACOG meeting, experts and attendees discussed the implications of these findings for improving contraceptive options and the importance of considering patient preferences. Viatris's ongoing research reflects a commitment to addressing the diverse needs of women and expanding the choices available in hormonal contraceptives.
